October 14, 2021

Proteomedix presents at the annual congress of the Italian Society of Urology in Riccione and the Society of Urologists in Private Hospitals in Modena.

Zurich-Schlieren, Switzerland, 14 October 2021 - Proteomedix, a Swiss company active in the field of prostate cancer diagnosis, will present at the annual congress of the Italian Society of Urology in Riccione and at the Society of Urologists in Private Hospitals in Modena.

After the limitations due to the COVID-19 pandemic that forced the cancellation of the most important national urology congresses, or to carry them out remotely in "virtual" mode, both the congresses of the Italian Society of Urology (Riccione, 16-19 October) the one of the Society of Urologists in Private Hospitals (Modena, 11-13 November) will take place again "in person". In both cases, Proteomedix will be present, bringing its flagship product, Proclarix, to the attention of the urologist community. A lecture on the updates of the diagnostic-prognostic path of patients with prostate cancer is included in the official scientific program of the URoP Congress, speaker Dr. Matteo Ferro from the European Institute of Oncology in Milan.

About Proclarix®
Proclarix® is CE-IVD marked and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient`s risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer.

About Proteomedix
Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score currently available in Europe. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland. For more information, visit www.proteomedix.com.

For further details, please contact:
Dr Maurizio Ballerini (MD), VP Market Development EMEA
+39 3487822703

Download Press Release in Italian